Skip to main content

RA/Inflammatory arthritis

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Aug 06, 2020

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  



In the last 2 years, observational data has

Read Article

Wearable Technology to Measure Arthritis Outcomes

Aug 04, 2020

In this lockdown, virtual medicine, post-COVID world, wouldn't it be ideal to have an reliable digital readout on patient activity as a measure of health? A multicenter study from the University of Nebraska Medical Center and the University of Alabama at Birminghams have completed a novel

Read Article

Lovastatin Fails to Lower CRP and Activity in RA

Aug 04, 2020

Ridker and colleagues have shown that statins (3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors) are effective at treating hyperlipidaemia and lowering C-reactive protein levels; Aranaow and colleagues have shown that lovastatin, when given to rheumatoid arthritis (RA)

Read Article

Fighting Hydroxychloroquine Misinformation

Aug 03, 2020

JAMA Internal Medicine has posted an Editor's note on the use of hydroxychloroquine for COVID-19; noting the sequence of dysfunction since the president promoted its use on March 21, 2020, when he said “What do you have to lose? I’ll say it again: What do you have to lose? Take it

Read Article

RheumNow Podcast - Top 13 Rheumatology Centers (7-31-20)

Jul 31, 2020

Dr. Jack Cush reviews the news and TOP 13 list of Best Rheumatology Hospitals.

Read Article

SEMIRA Study: Best to Continue Low Dose Steroids in RA

Jul 28, 2020

The SEMIRA trial studied the  tapering vs continuing oral glucocorticoids in rheumatoid arthritis (RA) patients who achieved a low disease activity state (with tocilizumab) were more likely to show safety and better disease control with continuing steroids - even though two-thirds of patients

Read Article

Low Risk of COVID in Biologic Treated Rheum Patients

Jul 23, 2020

In an Annals of Rheumatic Disease report, Italian investigators performed consecutive testing for SARS-CoV-2 (IgM and IgG) between 25 March to 25 May 2020 and compared test results between rheumatic disease (RMD) patients and the general population. 



Their study included 295

Read Article

For TNF Response in RA, Weight Matters

Jul 22, 2020

Patients with rheumatoid arthritis (RA) who were obese were significantly less likely to remain on treatment with tumor necrosis factor (TNF) inhibitors -- but so were those who were underweight, a large, long-term study determined.

Compared with patients with normal weight, patients in obesity

Read Article
Genotyping and microbiota data TwinsUK study (excluding RA) shows that Prevotella spp were positively assoc with RA risk; further validated by first-degree relatives of RA patients where Prevotella was assoc w/ HLA-DRB1 & preclinical arthritis.

Dr. John Cush RheumNow ( View Tweet)

Jul 20, 2020

PRIME Cells Predicting Rheumatoid Arthritis Flares

Jul 16, 2020

The current issue of NEJM reports a novel cell type that may be used to identify rheumatoid arthritis (RA) patients who may flare. 

Investigators prospectively collected blood samples from 4 patients for longitudinal RNA sequencing (RNA-seq) for discovery of moleculartranscripts that were

Read Article
Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01].

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020
Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis.

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020
The preliminary #ACR20 schedule is here! Along with all your favorite plenary and networking sessions, the program will feature #Rheumatologist Dr. Anthony Fauci giving us a live update on #COVID19.

Victoria Shanmugam VickiShanmugam ( View Tweet)

Jul 16, 2020
Italian report of 2 cases (1 w/ stable RA;1 without prior arthritis) who developed polyarthritis after hospitalization for COVID pneumonia. Synovial Bx showed synovial proliferation - 1 w/ crystals and both w/ CD3+ and CD138+ cells https://t.co/ZRRrWIjZXg

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020
Rheumatology reports a UK study of Clinical Practice Research Datalink and 17 760 incident RA pts; 42% who recv steroids; The HTN rate was 64.1 per 1000 PY & GC use assoc w/ 17% increased risk HTN (hazard ratio 1.17), esp at doses > 7.5 mg/d https://t.co/31Q2

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2020
Canadian 1484 incident early #RA pts (enrolled 2007–2017). SC MTX monotherapy had fewer Rx changes(45% SC vs 79% PO)with longer treatment duration. Similarly taking biologics or triple therapy had a longer time without treatment change. https://t.co/babj1MvTNB

Dr. John Cush RheumNow ( View Tweet)

Jul 15, 2020
NEW #COVID19—"Symmetric peripheral polyarthritis developed during #SARSCoV2 infection" Comment by Rosario Talarico and colleagues https://t.co/IqHp2GMLao #LancetRheumatology https://t.co/v3MBNDUnzG
The Lancet Rheumatology TheLancetRheum ( View Tweet)
Jul 14, 2020

JAK Inhibitor Succeeds as Monotherapy in Rheumatoid Arthritis

Jul 14, 2020

The oral Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) given as monotherapy was more effective than methotrexate alone in methotrexate-naive patients with active rheumatoid arthritis (RA) in a multinational phase III trial.

Read Article
FDA has approved a 6th adalimumab biosimilar - called Hulio (adalimumab-fkjp) with indications of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 13, 2020
Check my updated virtual video joint exam for rheumatologists - Video here> https://t.co/ZXEUKcw5mb or listen to the podcast>> https://t.co/XSHWuwxJ9L https://t.co/lBtG0lvAZM
Dr. John Cush RheumNow ( View Tweet)
Jul 13, 2020
H2H UPA vs ABA RCT; UPA is clinically superior to ABA in DAS-CRP remission, ACR50, ACR70 at wk 12/24 (NOT diff in P… https://t.co/7lwVCSYjPu

Dr. John Cush RheumNow ( View Tweet)

Jul 09, 2020
Rheumatology Round-Up from #EULAR2020 w/ Drs. Kavanaugh & Cush.

Dr. John Cush RheumNow ( View Tweet)

Jul 07, 2020

ICYMI: The Nine Lives of Hydroxychloroquine (Updated)

Hydroxychloroquine is one of many medications frequently used in rheumatology practice. Its remarkable versatility is attested by its routine use in lupus, in patients with an autoimmune coagulopathy, in patients with rheumatoid arthritis, as well as in those with a low-level inflammatory

Read Article
Case Controlled Study of 482 RA patients with ILD vs 741 RA w/o IL found an inverse relationship Between MTX exposu… https://t.co/ljtaKO8pVZ

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2020
Rheumatologist Question: early on, what do you tell your RA patient their chance of future drug free remission?

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2020
×